Silverarc Capital Management LLC Makes New Investment in Delcath Systems, Inc. (NASDAQ:DCTH)

Silverarc Capital Management LLC purchased a new position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 155,325 shares of the company's stock, valued at approximately $1,870,000. Silverarc Capital Management LLC owned about 0.49% of Delcath Systems as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DCTH. Quantbot Technologies LP purchased a new position in shares of Delcath Systems in the fourth quarter valued at approximately $66,000. Barclays PLC purchased a new stake in Delcath Systems during the 3rd quarter valued at about $104,000. Jane Street Group LLC acquired a new stake in Delcath Systems in the 3rd quarter valued at about $110,000. Private Advisor Group LLC purchased a new position in Delcath Systems in the 4th quarter worth approximately $153,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Delcath Systems during the fourth quarter worth approximately $156,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Delcath Systems Price Performance

Shares of DCTH traded down $0.19 during mid-day trading on Friday, reaching $11.88. The company's stock had a trading volume of 20,951 shares, compared to its average volume of 354,495. The stock has a market cap of $397.02 million, a PE ratio of -8.78 and a beta of 0.85. Delcath Systems, Inc. has a 12-month low of $5.04 and a 12-month high of $16.97. The company's 50 day moving average is $12.78 and its 200 day moving average is $12.34.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). The firm had revenue of $15.10 million for the quarter, compared to analysts' expectations of $14.96 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. During the same quarter in the prior year, the business earned ($0.48) EPS. As a group, sell-side analysts anticipate that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on DCTH. HC Wainwright increased their target price on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, March 7th. Craig Hallum boosted their target price on Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $22.75.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.